Author argues KLRS is an asymmetric long setup based on credible anti-VEGF science, durable Phase 1a data, low enterprise value, no near-term dilution, and tight float with high short interest.
KLRS — LONG Author argues KLRS offers asymmetry because TH103 was designed by the inventor of anti-VEGF therapy and Phase 1a showed +10 letter vision gain, ~95% fluid reduction, and 31% needing no retreatment for six months, which could extend dosing intervals in a $13-15B anti-VEGF market. The company trades at roughly $167M market cap with ~$120M cash (EV ~$90M), is funded into Q3 2027 with no forced raise before Phase 1b/2 data, and has ~82% insider ownership, ~28% short float, ~7.6 days to cover, and a ~$5M insider buy post-data. The catalyst is Phase 1b/2 durability data in H2 2026, where if durability holds, supply rather than demand becomes the problem. Main stated risk is that the thesis depends on durability holding in Phase 1b/2.
If durability holds in Phase 1b/2 (H2 2026), supply becomes the problem. Not demand
This Reddit post, published February 23, 2026, features u/CobraCodes discussing KLRS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/CobraCodes · Tickers: KLRS